Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $35.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Loop Capital set a $35.00 price target on Stoke Therapeutics in a research note on Monday, January 5th. Wolfe Research started coverage on Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target on the stock. UBS Group set a $50.00 price objective on Stoke Therapeutics in a research note on Monday, December 15th. Finally, Wedbush raised their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.83.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $31.02 on Wednesday. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $40.22. The company has a market capitalization of $1.83 billion, a PE ratio of 46.30 and a beta of 1.07. The company has a fifty day moving average of $32.61 and a 200-day moving average of $29.90.

Insider Transactions at Stoke Therapeutics

In other news, insider Arthur Tzianabos sold 4,355 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the completion of the transaction, the insider directly owned 31,339 shares in the company, valued at $1,253,560. This trade represents a 12.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adrian R. Krainer sold 33,243 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the transaction, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,203 shares of company stock worth $1,517,541 in the last quarter. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter worth approximately $26,000. Harbour Investments Inc. increased its position in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the period. Generali Investments Management Co LLC bought a new position in Stoke Therapeutics during the third quarter worth $41,000. BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised targets/maintained buy ratings — Needham bumped its target to $40 (buy), Wedbush raised its target to $38 (outperform), and Chardan reaffirmed a buy with a $35 target; these actions signal continued analyst confidence and potential upside. Analyst Coverage
• Neutral Sentiment: Inducement equity grants — Stoke granted 58,650 stock options to six new hires (effective Mar 16, 2026). This helps recruit talent but creates potential future dilution that investors should monitor. Inducement Grants Release
• Negative Sentiment: Quarterly results missed expectations — Stoke reported EPS of ($0.97) vs. consensus ($0.75) and revenue of $1.4M vs. $5.32M expected. The larger-than-expected EPS loss and significant revenue shortfall are the primary drivers of downward pressure on the stock. Quarterly Earnings Report
• Negative Sentiment: Insider sale — Director Arthur A. Levin sold 605 shares at an average $36.80 (reducing his stake ~12.5%). The sale is modest in dollar terms but can be interpreted negatively by some investors given the timing relative to the price. SEC Form 4

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.